One of the populations most vulnerable to persistent NMJ dysfunction after SMN-dependent treatments are adult SMA patients, as it is likely that some motoneuron loss has already occurred by the time SMN-based treatment is initiated. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.